Adults with multiple sclerosis and associated walking impairment in England are now eligible for NHS treatment with fampridine, bringing prescribing access in line with Scotland, Wales, and Northern Ireland, according to an NHS England statement published on July 23, 2026. The twice-daily tablet helps nerve signalling by retaining potassium, boosting walking speed by an average of 25% for responsive patients, according to data from the MS Society.
NHS England Treatment Criteria and Patient Eligibility
NHS England estimates the rollout will benefit approximately 5,000 patients during its first year. The therapy was formally recommended via a clinical commissioning policy published on July 16, 2026. Treatment is restricted to adult patients with an Expanded Disability Status Scale score between 4, meaning they can walk over 500 meters without rest, and 7, denoting individuals restricted to a wheelchair for about 12 hours a day who cannot walk five meters even with an aid.
Patients must discontinue the medication if their walking speed does not improve by more than 20% after an initial trial period of two to four weeks. Clinical trial results cited in the commissioning policy indicate the medication proves effective in roughly 43% of MS patients with walking impairment. However, data from Wales over the past year shows a higher proportion of patients remaining on the therapy, suggesting potential for similar outcomes in English clinics.
Did you know? Fampridine is also known by the brand name Fampyra and is manufactured by Merz Therapeutics, though the UK patent ends in July 2026, allowing the Medicines and Healthcare products Regulatory Agency to approve several generic versions.
Financial Factors and Cross-Nation Disparities
Access to fampridine has varied significantly across the UK for years. Wales added the treatment to NHS availability in 2019, followed by Scotland in 2020 and Northern Ireland in 2023. In England, a 2022 review by the National Institute for Health and Care Excellence concluded the medicine was not cost-effective at its previous list price.
Ceri Smith, head of policy and evidence at the MS Society, told The Pharmaceutical Journal on July 23, 2026, that a reduction in the drug’s cost served as a key trigger for NHS England’s policy change. Prior to this NHS commissioning decision, private access cost patients between £200 and £600 per month. Smith described the medication as transformative, noting that beyond improving walking speed, it aids dexterity and fatigue management, helping patients stay employed.
Pro Tip: NICE guidelines advise avoiding fampridine in patients with a history of renal failure or epilepsy, or those taking cimetidine or dolutegravir, as these medications can increase fampridine concentration in the body.
Implementation Challenges for Local Health Services
Despite the national policy rollout, charity representatives warn that local implementation may face hurdles. Because the therapy was recommended through an NHS England commissioning policy rather than a standard NICE appraisal, integrated care boards face no strict requirement to add the drug to their formularies or maintain regular prescribing routines.
Smith noted that stretched hospital and neurology services will require administrative and resource support to establish dedicated prescribing clinics. NHS England stated that the specialized treatment will be funded and reimbursed centrally under existing cost and volume arrangements for high-cost drugs.
Frequently Asked Questions
Who qualifies for NHS fampridine treatment in England?
Adults with multiple sclerosis who have an Expanded Disability Status Scale score between 4 and 7 and experience walking impairments qualify, subject to a clinical assessment and a 20% walking speed improvement threshold after four weeks.
How much does fampridine improve walking speed?
According to the MS Society, the medication improves walking speed by an average of 25% in responsive patients by retaining potassium in the nerves to aid signalling.
Is fampridine suitable for every MS patient?
No. Clinical trials show the drug is effective in about 43% of patients with walking impairment. It is also contraindicated for individuals with a history of epilepsy or renal failure, or those taking specific interacting drugs like cimetidine or dolutegravir.